In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AnaBios Corp.

www.anabios.com

Latest From AnaBios Corp.

Deal Watch: Purdue Continues Move Away From Opioids With Alivio Deal

In its continuing efforts to diversify away from opioid pain drugs, Purdue partners on non-opioid program with Alivio. Rigel licenses Tavalisse rights in all indications go to Spain’s Grifols.

Deals Business Strategies

Deal Watch: Roche Goes All-In On Real-World Data With Flatiron Acquisition

Already a significant investor in the health care technology firm, buyout will give Roche access to substantial real-world cancer development data. Astellas acquires stem cell-focused Universal Cells.

Deals Business Strategies

Venture Funding Deals: Stem Cell Venture BlueRock Launches With Major Funding

With backing from Bayer and others, the US-based venture will develop iPSC therapies for cardiovascular and neurodegenerative diseases; other notable new financings involve Cerevance, Goldfinch Bio, NeuroPharma and Tenaya. Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced November through December 2016.

Deals Financing

Pain Licensing: Upfront Gains Fall As Deals Get More Experimental

229 alliance deals were signed in the pain management sector between 2012 and November 2016, worth more than $1bn in upfront payments and around $11bn in total potential value. But an increase in deals for riskier, earlier stage assets has pushed down upfront payment values for the sector, knocking it out of sync with other therapy areas.

Deals Neurology
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
  • Contract Research, Toxicology Testing-CRO
  • Pharmaceuticals
  • Services
  • Therapeutic Areas
  • Cardiovascular
  • Hepatic (Liver)
  • Neurology, Nervous System
  • Renal System
  • Alias(es)
  • AnaBioCardia Corp.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • AnaBios Corp.
  • Senior Management
  • Andre Ghetti, PhD, CEO
    Howard Sampson, CFO
    Paul Miller, Chief Corp. Dev. Officer
    Najah Abi-Gerges, PhD, VP, R&D
  • Contact Info
  • AnaBios Corp.
    Phone: (858) 366-8608
    3030 Bunker Hill St.
    Ste. 312
    San Diego, CA 92109
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register